Browse > Article
http://dx.doi.org/10.4110/in.2014.14.3.123

Interleukin-32 in Inflammatory Autoimmune Diseases  

Kim, Soohyun (Department of Biomedical Sciences and Technology, Konkuk University)
Publication Information
IMMUNE NETWORK / v.14, no.3, 2014 , pp. 123-127 More about this Journal
Abstract
Interleukin-32 (IL-32) is a cytokine inducing crucial inflammatory cytokines such as tumor necrosis factor-${\alpha}(TNF{\alpha})$ and IL-6 and its expression is elevated in various inflammatory autoimmune diseases, certain cancers, as well as viral infections. IL-32 gene was first cloned from activated T cells, however IL-32 expression was also found in other immune cells and non-immune cells. IL-32 gene was identified in most mammals except rodents. It is transcribed as multiple-spliced variants in the absence of a specific activity of each isoform. IL-32 has been studied mostly in clinical fields such as infection, autoimmune, cancer, vascular disease, and pulmonary diseases. It is difficult to investigate the precise role of IL-32 in vivo due to the absence of IL-32 gene in mouse. The lack of mouse IL-32 gene restricts in vivo studies and restrains further development of IL-32 research in clinical applications although IL-32 new cytokine getting a spotlight as an immune regulatory molecule processing important roles in autoimmune, infection, and cancer. In this review, we discuss the regulation and function of IL-32 in inflammatory bowel diseases and rheumatoid arthritis.
Keywords
Cytokine; Inflammatory diseases; Inflectional immune responses; Immune cell differentiation; Inflammatory cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Zivojinovic, S. M., N. N. Pejnovic, M. N. Sefik-Bukilica, L. V. Kovacevic, I. I. Soldatovic, and N. S. Damjanov. 2012. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis. J. Rheumatol. 39: 18-21.   DOI
2 Heinhuis, B., M. I. Koenders, P. L. van Riel, F. A. van de Loo, C. A. Dinarello, M. G. Netea, W. B. van den Berg, and L. A. Joosten. 2011. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann. Rheum. Dis. 70: 660-667.   DOI   ScienceOn
3 Heinhuis, B., M. I. Koenders, F. A. van de Loo, M. G. Netea, W. B. van den Berg, and L. A. Joosten. 2011. Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 108: 4962-4967.   DOI   ScienceOn
4 Alsaleh, G., L. Sparsa, E. Chatelus, M. Ehlinger, J. E. Gottenberg, D. Wachsmann, and J. Sibilia. 2010. Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res. Ther. 12: R135.   DOI
5 Kim, S. H., S. Y. Han, T. Azam, D. Y. Yoon, and C. A. Dinarello. 2005. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22: 131-142.
6 Choi, J. D., S. Y. Bae, J. W. Hong, T. Azam, C. A. Dinarello, E. Her, W. S. Choi, B. K. Kim, C. K. Lee, D. Y. Yoon, S. J. Kim, and S. H. Kim. 2009. Identification of the most active interleukin-32 isoform. Immunology 126: 535-542.   DOI   ScienceOn
7 Kim, Y. G., C. K. Lee, J. S. Oh, S. H. Kim, K. A. Kim, and B. Yoo. 2010. Effect of interleukin-32gamma on differentiation of osteoclasts from $CD14^+$ monocytes. Arthritis Rheum. 62: 515-523.
8 Moon, Y. M., B. Y. Yoon, Y. M. Her, H. J. Oh, J. S. Lee, K. W. Kim, S. Y. Lee, Y. J. Woo, K. S. Park, S. H. Park, H. Y. Kim, and M. L. Cho. 2012. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res. Ther. 14: R246.   DOI   ScienceOn
9 Xu, W. D., M. Zhang, C. C. Feng, X. K. Yang, H. F. Pan, and D. Q. Ye. 2013. IL-32 with potential insights into rheumatoid arthritis. Clin. Immunol. 147: 89-94.   DOI   ScienceOn
10 Joosten, L. A., M. G. Netea, S. H. Kim, D. Y. Yoon, B. Oppers-Walgreen, T. R. Radstake, P. Barrera, F. A. van de Loo, C. A. Dinarello, and W. B. van den Berg. 2006. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad Sci. USA 103: 3298-3303.   DOI   ScienceOn
11 Gui, M., H. Zhang, K. Zhong, Y. Li, J. Sun, and L. Wang. 2013. Clinical significance of interleukin-32 expression in patients with rheumatoid arthritis. Asian Pac. J. Allergy Immunol. 31: 73-78.
12 Jeong, H. J., H. A. Oh, B. J. Lee, and H. M. Kim. 2014. Inhibition of IL-32 and TSLP production through the attenuation of caspase-1 activation in an animal model of allergic rhinitis by Naju Jjok (Polygonum tinctorium). Int. J. Mol. Med. 33: 142-150.   DOI
13 Cagnard, N., F. Letourneur, A. Essabbani, V. Devauchelle, S. Mistou, A. Rapinat, C. Decraene, C. Fournier, and G. Chiocchia. 2005. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur. Cytokine Netw. 16: 289-292.
14 Shioya, M., A. Nishida, Y. Yagi, A. Ogawa, T. Tsujikawa, S. Kim-Mitsuyama, A. Takayanagi, N. Shimizu, Y. Fujiyama, and A. Andoh. 2007. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin. Exp. Immunol. 149: 480-486.   DOI   ScienceOn
15 Ciccia, F., A. Rizzo, A. Accardo-Palumbo, A. Giardina, M. Bombardieri, G. Guggino, S. Taverna, G. D. Leo, R. Alessandro, and G. Triolo. 2012. Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients. Rheumatology (Oxford) 51: 1966-1972.   DOI   ScienceOn
16 Andoh, A., Y. Yagi, M. Shioya, A. Nishida, T. Tsujikawa, and Y. Fujiyama. 2008. Mucosal cytokine network in inflammatory bowel disease. World J. Gastroenterol. 14: 5154-5161.   DOI
17 Fantini, M. C., G. Monteleone, and T. T. Macdonald. 2007. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1419-1423.   DOI   ScienceOn
18 Felaco, P., M. L. Castellani, M. A. De Lutiis, M. Felaco, F. Pandolfi, V. Salini, D. De Amicis, J. Vecchiet, S. Tete, C. Ciampoli, F. Conti, G. Cerulli, A. Caraffa, P. Antinolfi, C. Cuccurullo, A. Perrella, T. C. Theoharides, P. Conti, E. Toniato, D. Kempuraj, and Y. B. Shaik. 2009. IL-32: a newly-discovered proinflammatory cytokine. J. Biol. Regul. Homeost. Agents 23: 141-147.
19 Choi, J., S. Bae, J. Hong, S. Ryoo, H. Jhun, K. Hong, D. Yoon, S. Lee, E. Her, W. Choi, J. Kim, T. Azam, C. A. Dinarello, and S. Kim. 2010. Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis. Proc. Natl. Acad. Sci. USA 107: 21082-21086.   DOI   ScienceOn
20 Netea, M. G., E. C. Lewis, T. Azam, L. A. Joosten, J. Jaekal, S. Y. Bae, C. A. Dinarello, and S. H. Kim. 2008. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc. Natl. Acad. Sci. USA 105: 3515-3520.   DOI   ScienceOn
21 Netea, M. G., T. Azam, G. Ferwerda, S. E. Girardin, M. Walsh, J. S. Park, E. Abraham, J. M. Kim, D. Y. Yoon, C. A. Dinarello, and S. H. Kim. 2005. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc. Natl. Acad. Sci. USA 102: 16309-16314.   DOI   ScienceOn
22 Imaeda, H., A. Andoh, T. Aomatsu, R. Osaki, S. Bamba, O. Inatomi, T. Shimizu, and Y. Fujiyama. 2011. A new isoform of interleukin-32 suppresses IL-8 mRNA expression in the intestinal epithelial cell line HT-29. Mol. Med. Rep. 4: 483-487.